Baker Brothers Life Sciences LP
CIK 1363364 · last filed 2026-06-18
Baker Brothers Life Sciences LP is a corporate insider who has filed 92 SEC Form 4 insider transactions across 23 companies since 2012. The most recent filing, for CELC, was dated Jul 14, 2026. Across all open-market trades the lifetime net is +$5.81B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.48B across reported positions. The firm reports its address in New York, NY. 525 SEC filings were submitted jointly with BAKER BROS. ADVISORS LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.48B
23
92
$5.81B
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 1,948,876 | $534.49 | $1.04B | $221.65M | 2 | 2026-06-18 |
| INCY | Director | 3,098,808 | $121.47 | $376.41M | $390.15M | 15 | 2026-01-05 |
| KYMR | Director | 7,955,916 | $114.96 | $914.61M | $1.03B | 1 | 2025-12-11 |
| PRLD | Director | — | $4.59 | — | $0 | 2 | 2025-06-13 |
| REPL | Director | — | $12.92 | — | $0 | 1 | 2025-03-07 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,759,462 | $1.27 | $4.77M | $0 | 5 | 2024-10-02 |
| VTVT | Director | — | $31.97 | — | $0 | 1 | 2024-06-27 |
| ACAD | Director | 39,452,627 | $27.83 | $1.10B | $900.00M | 4 | 2024-05-31 |
| BCYC | Director | — | $3.86 | — | $0 | 1 | 2024-05-29 |
| TCRX | Director | 104,698 | $0.32 | $33.5K | $128.25M | 3 | 2024-04-23 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 93,418 | $184.71 | $17.26M | -$1.19B | 3 | 2023-11-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 116,457 | $13.96 | $1.63M | $160.87M | 2 | 2023-08-17 |
| KOD | Director | 1,143,396 | $32.89 | $37.61M | $1.08B | 4 | 2022-07-05 |
| DBVT | Director | 1,341,390 | $11.85 | $15.90M | $0 | 1 | 2022-06-13 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-06-10 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 466,878 | $2.84 | $1.33M | $600.00M | 1 | 2021-02-19 |
| KNSA | Director | — | $76.27 | — | $0 | 1 | 2020-05-18 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 166,122 | — | — | -$403.77M | 11 | 2019-04-10 |
| Neurogene Inc. (AQXP) Delisted | Director | — | — | — | $0 | 1 | 2018-05-09 |
| Seagen Inc. (SGEN) Delisted | Director | 44,865,178 | $228.74 | $10.26B | $2.16B | 6 | 2018-05-02 |
| Aceragen, Inc. (IDRA) Delisted | Director | 242,126 | $7.22 | $1.75M | $0 | 8 | 2018-04-04 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 23,372 | $40.17 | $938.9K | -$62.10M | 5 | 2015-07-23 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 144,482 | — | — | $778.06M | 3 | 2015-01-09 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-14 | CELC | Notice (144) | −2,838,632 | -$290.96M | EDGAR |
| 2026-06-18 | MDGL | Grant (A) | +10,896 | $0 | EDGAR |
| 2026-04-23 | TARA | Notice (144) | −300,176 | -$1.61M | EDGAR |
| 2026-03-06 | TARA | Notice (144) | −461,723 | -$2.70M | EDGAR |
| 2026-03-04 | TARA | Notice (144) | −424,125 | -$2.65M | EDGAR |
| 2026-02-25 | TARA | Notice (144) | −947,479 | -$5.50M | EDGAR |
| 2026-02-24 | TARA | Notice (144) | −322,039 | -$1.94M | EDGAR |
| 2026-01-05 | INCY | Grant (A) | +3,936 | $0 | EDGAR |
| 2025-12-11 | KYMR | Buy (P) | +12,034,878 | $1.03B | EDGAR |
| 2025-10-02 | INCY | Grant (A) | +4,656 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.